In addition, the combination of ibrutinib and a BCL-2 antagonist showed additive or more than additive cytotoxicity in vitro against CLL cells from patients treated with ibrutinib [28]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.